Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative

American Heart Journal

Volumn 158, Issue 3, 2009, Pages 317-326

  Piccini, Jonathan P ^a   Whellan, David J ^b   Berridge, Brian R ^c   Finkle, John K ^c   Pettit, Syril D ^e   Stockbridge, Norman ^d   Valentin, Jean Pierre ^f   Vargas, Hugo M ^g   Krucoff, Mitchell W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f ASTRAZENECA   (United Kingdom)

^g AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ASTEMIZOLE; BIOLOGICAL MARKER; CISAPRIDE; FLOSEQUINAN; GREPAFLOXACIN; PHENOBARBITAL; POTASSIUM CHANNEL HERG; QUETIAPINE; RANOLAZINE; ROFECOXIB; TERFENADINE; TERODILINE; TROPONIN; VALDECOXIB; VERAPAMIL;

ACTION POTENTIAL DURATION; BIOASSAY; BLOOD PRESSURE; BLOOD TOXICITY; BONE MARROW TOXICITY; CARCINOGENICITY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL PATHWAY; DRUG DEVELOPMENT; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG SAFETY; ELECTROCARDIOGRAM; HEART; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HEART RATE; HUMAN; LIVER TOXICITY; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT DISPERSION; QT PROLONGATION; REVIEW; SIDE EFFECT; STANDARD; T WAVE; THROMBOCYTE; TORSADE DES POINTES;

ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CRITICAL PATHWAYS; DRUG EVALUATION; DRUG TOXICITY; ELECTROCARDIOGRAPHY; HEART DISEASES; HUMANS; RESEARCH; RISK MANAGEMENT; SAFETY; TECHNOLOGY TRANSFER; TROPONIN;

EID: 68949149740     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.06.007     Document Type: Review

References (50)

1. Fung M., Thorton A., Mybeck K., et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceuticals markets - 1960 to 1999. Drug Inf J 35 (2001) 293-317
2. Stephens M. Introduction. In: Talbot J., and Waller P. (Eds). Stephens' Detection of New Adverse Drug Reactions. 5th ed. (2004), John Wiley and Sons, Ltd., Maiden (MA) 1-91
3. Astemizole: voluntary withdrawal: Janssen, USA (1999), WHO Pharmaceuticals Newsletter (07 and 08)
4. Henney J.E. Withdrawal of troglitazone and cisapride. JAMA 283 (2000) 2228
5. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
6. Packer M., Rouleau J., Swedberg K., et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE trial. Circulation 88 Suppl I (1993) I-301
7. Owens Â.J., Robert Â.C., and Ambrose Paul Â.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41 (2005) S144-S157
8. Garber A.M. An uncertain future for cardiovascular drug development?. N Engl J Med 360 (2009) 1169-1171
9. Sun S.X., Lee K.Y., Bertram C.T., et al. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 23 (2007) 1859-1866
10. FDA announces plan to halt marketing of terfenadine. Am J Health Syst Pharm 54 (1997) 342-
11. Shah R. Withdrawal of terodiline: a tale of two toxicities. In: Mann R., and Andrews E. (Eds). Pharmacovigilance (2002), John Wiley and Sons, Ltd., London
12. Pitts P.J. FDA and the critical path to twenty-first-century medicine. J Med Philos 33 (2008) 515-523
13. O'Brien P.J., Dameron G.W., Beck M.L., et al. Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sci 47 (1997) 486-495
14. O'Brien P.J. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 245 (2008) 206-218
15. Apple F.S., Murakami M.M., Ler R., et al. Analytical characteristics of commercial cardiac troponin I and T immunoassays in serum from rats, dogs, and monkeys with induced acute myocardial injury. Clin Chem 54 (2008) 1982-1989
16. Jaffe A. Elevations in cardiac troponin measurements: false false-positives. Cardiovasc Toxicol 1 (2001) 87-92
17. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004) 1013-1022
18. Drolet B., Khalifa M., Daleau P., et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97 (1998) 204-210
19. Monahan B.P., Ferguson C.L., Killeavy E.S., et al. Torsades de pointes occurring in association with terfenadine use. JAMA 264 (1990) 2788-2790
20. Scirica B.M., Morrow D.A., Hod H., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation 116 (2007) 1647-1652
21. Cavero I., and Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Ex Opin Drug Saf 4 (2005) 509-530
22. Lehmann M.H., Hardy S., Archibald D., et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 94 (1996) 2535-2541
23. Vargas H.M., Bass A.S., Breidenbach A., et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58 (2008) 72-76
24. Shah R.R., and Hondeghem L.M. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2 (2005) 758-772
25. Food and Drug Administration, HHS. International conference on harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 70 (2005) 61134-61135
26. Kligfield P., Hancock E.W., Helfenbein E.D., et al. Relation of QT interval measurements to evolving automated algorithms from different manufacturers of electrocardiographs. Am J Cardiol 98 (2006) 88-92
27. Couderc J.P., McNitt S., Hyrien O., et al. Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin. Drug Saf 31 (2008) 249-260
28. Couderc J-P, Zhou M, Sarapa N, et al. Investigating the effect of sotalol on the repolarization intervals in healthy young individuals. J Electrocardiol [in press], Corrected proof.
29. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 12 (2001) 411-420
30. Marek M., Hnatkova K., Batchvarov V., et al. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 27 (2004) 1659-1669
31. Piccini J., and Zaas A. Cases from the Osler Medical Service at Johns Hopkins University. Am J Med 115 (2003) 70-71
32. Varriale P., and Ramaprasad S. Aminophylline induced atrial fibrillation. Pacing Clin Electrophysiol 16 (1993) 1953-1955
33. Lehtonen A., Fodstad H., Laitinen-Forsblom P., et al. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 4 (2007) 603-607
34. Yang P., Kanki H., Drolet B., et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105 (2002) 1943-1948
35. Lord P.G., and Papoian T. Genomics and drug toxicity. Science 306 (2004) 575
36. + channel by the scorpion toxin CnErg1. Biophys. J. 92 (2007) 3915-3929
37. Charbit B., Funck-Brentano C., Samain E., et al. QT interval prolongation after oxytocin bolus during surgical induced abortion. Clin Pharmacol Ther 76 (2004) 359-364
38. Cordes J.S., Sun Z., Lloyd D.B., et al. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145 (2005) 15-23
39. Mascelli M.A., Zhou H., Sweet R., et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol 47 (2007) 553-565
40. Fernández-Velasco M., Ruiz-Hurtado G., Hurtado O., et al. TNF-alpha downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation. Am J Physiol Heart Circ Physiol 293 (2007) H238-H245
41. Giezen T.J., Mantel-Teeuwisse A.K., Straus S.M., et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300 (2008) 1887-1896
42. Grazette L.P., Boecker W., Matsui T., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44 (2004) 2231-2238
43. Lynch III J.J., Wilson A.W., Hernandez L.E., et al. Dose response effects of sotalol on cardiovascular function in conscious, freely moving cynomolgus monkeys. Br J Pharmacol 154 (2008) 1439-1445
44. Haydar A.A., Covic A., Jayawardene S., et al. Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation 77 (2004) 849-853
45. Toprak A., Koc M., Tezcan H., et al. Night-time blood pressure load is associated with higher left ventricular mass index in renal transplant recipients. J Hum Hypertens 17 (2003) 239-244
46. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
47. Ahmad S.R. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med 18 (2003) 57-60
48. Kalantzis N., Gabriel P., Mouzas J., et al. Acute amiodarone-induced hepatitis. Hepatogastroenterology 38 (1991) 71-74
49. Kantelip J.P., Duchene-Marullaz P., Delaigue-Fabry R., et al. Comparison of the effects of propranolol, pindolol, oxprenolol and acebutolol on atrioventricular conduction in unanaesthetized dogs. Br J Clin Pharmacol 13 Suppl 2 (1982) 159S-166S
50. Weber M.A. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. Am J Med 84 (1988) 16-23